{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:35:07Z","timestamp":1778625307733,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T00:00:00Z","timestamp":1473724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T00:00:00Z","timestamp":1473724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malignant pleural mesothelioma (MPM) is an aggressive cancer that is commonly associated with prior asbestos exposure. Receptor tyrosine kinases (RTKs) such as MET and its downstream target PI3K are overexpressed and activated in a majority of MPMs. Here, we studied the combinatorial therapeutic efficacy of the MET\/ALK inhibitor crizotinib, with either a pan-class I PI3K inhibitor, BKM120, or with a PI3K\/mTOR dual inhibitor, GDC-0980, in mesothelioma. Cell viability results showed that MPM cells were highly sensitive to crizotinib, BKM120 and GDC-0980 when used individually and their combination was more effective in suppressing growth. Treatment of MPM cells with these inhibitors also significantly decreased cell migration, and the combination of them was synergistic. Treatment with BKM120 alone or in combination with crizotinib induced G2-M arrest and apoptosis. Both crizotinib and BKM120 strongly inhibited the activity of MET and PI3K as evidenced by the decreased phosphorylation of MET, AKT and ribosomal S6 kinase. Using a PDX mouse model, we showed that a combination of crizotinib with BKM120 was highly synergetic in inhibiting MPM tumor growth. In conclusion our findings suggest that dual inhibition of PI3K and MET pathway is an effective strategy in treating MPM as compared to a single agent.<\/jats:p>","DOI":"10.1038\/srep32992","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T15:00:43Z","timestamp":1473778843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma"],"prefix":"10.1038","volume":"6","author":[{"given":"Rajani","family":"Kanteti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob J.","family":"Riehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Immanuel","family":"Dhanasingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances E.","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Mirzapoiazova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bolot","family":"Mambetsariev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hedy L.","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,13]]},"reference":[{"key":"BFsrep32992_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/ncponc0839","volume":"4","author":"A Tsiouris","year":"2007","unstructured":"Tsiouris, A. & Walesby, R. K. Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol 4, 344\u2013352, 10.1038\/ncponc0839 (2007).","journal-title":"Nat Clin Pract Oncol"},{"key":"BFsrep32992_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1349-7006.2009.01336.x","volume":"101","author":"Y Sekido","year":"2010","unstructured":"Sekido, Y. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. CancereSci 101, 1\u20136, 10.1111\/j.1349-7006.2009.01336.x (2010).","journal-title":"CancereSci"},{"key":"BFsrep32992_CR3","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nm0897-913","volume":"3","author":"A De Luca","year":"1997","unstructured":"De Luca, A. et al. The retinoblastoma gene family pRb\/p105, p107, pRb2\/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat Med 3, 913\u2013916 (1997).","journal-title":"Nat Med"},{"key":"BFsrep32992_CR4","doi-asserted-by":"publisher","first-page":"5063","DOI":"10.1158\/0008-5472.CAN-05-4642","volume":"66","author":"AU Dogan","year":"2006","unstructured":"Dogan, A. U. et al. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 66, 5063\u20135068, 10.1158\/0008-5472.CAN-05-4642 (2006).","journal-title":"Cancer Res"},{"key":"BFsrep32992_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/cncr.21971","volume":"107","author":"JD Tward","year":"2006","unstructured":"Tward, J. D., Wendland, M. M. M., Shrieve, D. C., Szabo, A. & Gaffney, D. K. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 107, 108\u2013115, 10.1002\/cncr.21971 (2006).","journal-title":"Cancer"},{"key":"BFsrep32992_CR6","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21, 2636\u20132644, 10.1200\/JCO.2003.11.136 (2003).","journal-title":"J Clin Oncol"},{"key":"BFsrep32992_CR7","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"JP van Meerbeeck","year":"2005","unstructured":"van Meerbeeck, J. P. et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23, 6881\u20136889, 10.1200\/JCO.20005.14.589 (2005).","journal-title":"J Clin Oncol"},{"key":"BFsrep32992_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1055\/s-0031-1272874","volume":"32","author":"NP Campbell","year":"2011","unstructured":"Campbell, N. P. & Kindler, H. L. Update on malignant pleural mesothelioma. Semin Respir Crit Care Med 32, 102\u2013110, 10.1055\/s-0031-1272874 (2011).","journal-title":"Semin Respir Crit Care Med"},{"key":"BFsrep32992_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/35077225","volume":"411","author":"P Blume-Jensen","year":"2001","unstructured":"Blume-Jensen, P. & Hunter, T. Oncogenic kinase signalling. Nature 411, 355\u2013365, 10.1038\/35077225 (2001).","journal-title":"Nature"},{"key":"BFsrep32992_CR10","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/bjc.1990.207","volume":"61","author":"H Dazzi","year":"1990","unstructured":"Dazzi, H. et al. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. British journal of cancer 61, 924\u2013926 (1990).","journal-title":"British journal of cancer"},{"key":"BFsrep32992_CR11","doi-asserted-by":"publisher","first-page":"7479","DOI":"10.1158\/0008-5472.CAN-04-1898","volume":"64","author":"CD Hoang","year":"2004","unstructured":"Hoang, C. D. et al. Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. Cancer Res 64, 7479\u20137485, 10.1158\/0008-5472.CAN-04-1898 (2004).","journal-title":"Cancer Res"},{"key":"BFsrep32992_CR12","doi-asserted-by":"publisher","first-page":"455S","DOI":"10.1378\/chest.116.suppl_3.455S","volume":"116","author":"HI Pass","year":"1999","unstructured":"Pass, H. I., Robinson, B. W., Testa, J. R. & Carbone, M. Emerging translational therapies for mesothelioma. Chest 116, 455S\u2013460S (1999).","journal-title":"Chest"},{"key":"BFsrep32992_CR13","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/carcin\/bgp097","volume":"30","author":"K Kawaguchi","year":"2009","unstructured":"Kawaguchi, K. et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 30, 1097\u20131105, 10.1093\/carcin\/bgp097 (2009).","journal-title":"Carcinogenesis"},{"key":"BFsrep32992_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","volume":"66","author":"R Jagadeeswaran","year":"2006","unstructured":"Jagadeeswaran, R. et al. Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66, 352\u2013361, 10.1158\/0008-5472.CAN-04-4567 (2006).","journal-title":"Cancer Res"},{"key":"BFsrep32992_CR15","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1097\/JTO.0b013e31821528d3","volume":"6","author":"S-HI Ou","year":"2011","unstructured":"Ou, S.-H. I. et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 6, 942\u2013946, 10.1097\/JTO.0b013e31821528d3 (2011).","journal-title":"Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer"},{"key":"BFsrep32992_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11912-012-0227-y","volume":"14","author":"L Willems","year":"2012","unstructured":"Willems, L. et al. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep 14, 129\u2013138, 10.1007\/s11912-012-0227-y (2012).","journal-title":"Curr Oncol Rep"},{"key":"BFsrep32992_CR17","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/JTO.0b013e31811f3aab","volume":"2","author":"MR Patel","year":"2007","unstructured":"Patel, M. R. et al. Ras pathway activation in malignant mesothelioma. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2, 789\u2013795, 10.1097\/JTO.0b013e31811f3aab (2007).","journal-title":"Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer"},{"key":"BFsrep32992_CR18","doi-asserted-by":"publisher","first-page":"7455","DOI":"10.1038\/sj.onc.1209085","volume":"24","author":"DA Altomare","year":"2005","unstructured":"Altomare, D. A. & Testa, J. R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 24, 7455\u20137464, 10.1038\/sj.onc.1209085 (2005).","journal-title":"Oncogene"},{"key":"BFsrep32992_CR19","doi-asserted-by":"publisher","first-page":"e105919","DOI":"10.1371\/journal.pone.0105919","volume":"9","author":"R Kanteti","year":"2014","unstructured":"Kanteti, R. et al. MET and PI3K\/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PloS one 9, e105919, 10.1371\/journal.pone.0105919 (2014).","journal-title":"PloS one"},{"key":"BFsrep32992_CR20","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1158\/1535-7163.MCT-07-0365","volume":"6","author":"JG Christensen","year":"2007","unstructured":"Christensen, J. G. et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Molecular cancer therapeutics 6, 3314\u20133322, 10.1158\/1535-7163.MCT-07-0365 (2007).","journal-title":"Molecular cancer therapeutics"},{"key":"BFsrep32992_CR21","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.1158\/0008-5472.CAN-06-4443","volume":"67","author":"HY Zou","year":"2007","unstructured":"Zou, H. Y. et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67, 4408\u20134417, 10.1158\/0008-5472.CAN-06-4443 (2007).","journal-title":"Cancer Res"},{"key":"BFsrep32992_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2119\/molmed.2011.00238","volume":"18","author":"R Bu","year":"2012","unstructured":"Bu, R. et al. c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death. Mol Med 18, 167\u2013177, 10.2119\/molmed.2011.00238 (2012).","journal-title":"Mol Med"},{"key":"BFsrep32992_CR23","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1158\/1535-7163.MCT-11-0934","volume":"11","author":"W Okamoto","year":"2012","unstructured":"Okamoto, W. et al. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Molecular cancer therapeutics 11, 1557\u20131564, 10.1158\/1535-7163.MCT-11-0934 (2012).","journal-title":"Molecular cancer therapeutics"},{"key":"BFsrep32992_CR24","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-13-1897","volume":"20","author":"JD Valentino","year":"2014","unstructured":"Valentino, J. D. et al. Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors. Clin Cancer Res 20, 1212\u20131222, 10.1158\/1078-0432.CCR-13-1897 (2014).","journal-title":"Clin Cancer Res"},{"key":"BFsrep32992_CR25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1158\/1535-7163.MCT-11-0474","volume":"11","author":"S-M Maira","year":"2012","unstructured":"Maira, S.-M. et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Molecular cancer therapeutics 11, 317\u2013328, 10.1158\/1535-7163.MCT-11-0474 (2012).","journal-title":"Molecular cancer therapeutics"},{"key":"BFsrep32992_CR26","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/liv.12126","volume":"33","author":"MM Kirstein","year":"2013","unstructured":"Kirstein, M. M. et al. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma. Liver Int 33, 780\u2013793, 10.1111\/liv.12126 (2013).","journal-title":"Liver Int"},{"key":"BFsrep32992_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.canlet.2014.02.018","volume":"347","author":"J Roper","year":"2014","unstructured":"Roper, J. et al. Combination PI3K\/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. Cancer Lett 347, 204\u2013211, 10.1016\/j.canlet.2014.02.018 (2014).","journal-title":"Cancer Lett"},{"key":"BFsrep32992_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00432-014-1594-6","volume":"140","author":"PR Wachsberger","year":"2014","unstructured":"Wachsberger, P. R. et al. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma. J Cancer Res Clin Oncol 140, 573\u2013582, 10.1007\/s00432-014-1594-6 (2014).","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFsrep32992_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.canlet.2013.03.032","volume":"338","author":"H Ren","year":"2013","unstructured":"Ren, H. et al. The PI3 kinase inhibitor NVP-BKM120 induces GSK3\/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis. Cancer Lett 338, 229\u2013238, 10.1016\/j.canlet.2013.03.032 (2013).","journal-title":"Cancer Lett"},{"key":"BFsrep32992_CR30","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00280-013-2129-6","volume":"71","author":"M Serova","year":"2013","unstructured":"Serova, M. et al. Benchmarking effects of mTOR, PI3K, and dual PI3K\/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib. Cancer chemotherapy and pharmacology 71, 1297\u20131307, 10.1007\/s00280-013-2129-6 (2013).","journal-title":"Cancer chemotherapy and pharmacology"},{"key":"BFsrep32992_CR31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00109-011-0849-9","volume":"90","author":"Y Zheng","year":"2012","unstructured":"Zheng, Y. et al. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med 90, 695\u2013706, 10.1007\/s00109-011-0849-9 (2012).","journal-title":"J Mol Med"},{"key":"BFsrep32992_CR32","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3892\/ijo.2011.1290","volume":"40","author":"E Park","year":"2012","unstructured":"Park, E. et al. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. International journal of oncology 40, 1259\u20131266, 10.3892\/ijo.2011.1290 (2012).","journal-title":"International journal of oncology"},{"key":"BFsrep32992_CR33","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/1078-0432.CCR-11-1558","volume":"18","author":"D Koul","year":"2012","unstructured":"Koul, D. et al. Antitumor activity of NVP-BKM120\u2013a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 18, 184\u2013195, 10.1158\/1078-0432.CCR-11-1558 (2012).","journal-title":"Clin Cancer Res"},{"key":"BFsrep32992_CR34","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.leukres.2013.12.027","volume":"38","author":"FS Hamedani","year":"2014","unstructured":"Hamedani, F. S. et al. Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma. Leuk Res 38, 503\u2013508, 10.1016\/j.leukres.2013.12.027 (2014).","journal-title":"Leuk Res"},{"key":"BFsrep32992_CR35","doi-asserted-by":"publisher","first-page":"570","DOI":"10.4161\/cbt.28162","volume":"15","author":"C Ji","year":"2014","unstructured":"Ji, C. et al. Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. Cancer biology & therapy 15, 570\u2013577, 10.4161\/cbt.28162 (2014).","journal-title":"Cancer biology & therapy"},{"key":"BFsrep32992_CR36","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1158\/1535-7163.MCT-13-0499","volume":"12","author":"O Surriga","year":"2013","unstructured":"Surriga, O. et al. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model. Molecular cancer therapeutics 12, 2817\u20132826, 10.1158\/1535-7163.MCT-13-0499 (2013).","journal-title":"Molecular cancer therapeutics"},{"key":"BFsrep32992_CR37","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1158\/1535-7163.MCT-11-1021","volume":"11","author":"SM Brachmann","year":"2012","unstructured":"Brachmann, S. M. et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Molecular cancer therapeutics 11, 1747\u20131757, 10.1158\/1535-7163.MCT-11-1021 (2012).","journal-title":"Molecular cancer therapeutics"},{"key":"BFsrep32992_CR38","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/bjc.2014.61","volume":"110","author":"YJ Liu","year":"2014","unstructured":"Liu, Y. J. et al. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. British journal of cancer 110, 1169\u20131178, 10.1038\/bjc.2014.61 (2014).","journal-title":"British journal of cancer"},{"key":"BFsrep32992_CR39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/1471-2407-14-185","volume":"14","author":"R Kanteti","year":"2014","unstructured":"Kanteti, R. et al. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. BMC cancer 14, 185, 10.1186\/1471-2407-14-185 (2014).","journal-title":"BMC cancer"},{"key":"BFsrep32992_CR40","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/labinvest.2008.168","volume":"89","author":"R Kanteti","year":"2009","unstructured":"Kanteti, R. et al. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Laboratory investigation; a journal of technical methods and pathology 89, 301\u2013314, 10.1038\/labinvest.2008.168 (2009).","journal-title":"Laboratory investigation; a journal of technical methods and pathology"},{"key":"BFsrep32992_CR41","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58, 621\u2013681, 10.1124\/pr.58.3.10 (2006).","journal-title":"Pharmacol Rev"},{"key":"BFsrep32992_CR42","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1113\/jphysiol.2009.180331","volume":"587","author":"SN Saleh","year":"2009","unstructured":"Saleh, S. N., Albert, A. P. & Large, W. A. Activation of native TRPC1\/C5\/C6 channels by endothelin-1 is mediated by both PIP3 and PIP2 in rabbit coronary artery myocytes. J Physiol 587, 5361\u20135375, 10.1113\/jphysiol.2009.180331 (2009).","journal-title":"J Physiol"},{"key":"BFsrep32992_CR43","doi-asserted-by":"publisher","first-page":"e67668","DOI":"10.1371\/journal.pone.0067668","volume":"8","author":"BD Ferguson","year":"2013","unstructured":"Ferguson, B. D. et al. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PloS one 8, e67668, 10.1371\/journal.pone.0067668 (2013).","journal-title":"PloS one"},{"key":"BFsrep32992_CR44","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1091\/mbc.12.7.1983","volume":"12","author":"SH Kee","year":"2001","unstructured":"Kee, S. H. & Steinert, P. M. Microtubule disruption in keratinocytes induces cell-cell adhesion through activation of endogenous E-cadherin. Molecular biology of the cell 12, 1983\u20131993 (2001).","journal-title":"Molecular biology of the cell"},{"key":"BFsrep32992_CR45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1083\/jcb.99.1.115","volume":"99","author":"NC Zanetti","year":"1984","unstructured":"Zanetti, N. C. & Solursh, M. Induction of chondrogenesis in limb mesenchymal cultures by disruption of the actin cytoskeleton. The Journal of cell biology 99, 115\u2013123 (1984).","journal-title":"The Journal of cell biology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep32992.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32992","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32992.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T01:28:09Z","timestamp":1672882089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep32992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,13]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,16]]}},"alternative-id":["BFsrep32992"],"URL":"https:\/\/doi.org\/10.1038\/srep32992","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,13]]},"assertion":[{"value":"8 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32992"}}